4.7 Article

Cyclic Adenosine 5′-Diphosphate Ribose Analogs without a Southern Ribose Inhibit ADP-ribosyl Cyclase-Hydrolase CD38

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 20, Pages 8517-8529

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm501037u

Keywords

-

Funding

  1. Wellcome Trust [101010]
  2. [RCGAS 201105159001]
  3. [HK-GRF 766911]
  4. [HK-GRF HKU 785110M]

Ask authors/readers for more resources

Cyclic adenosine 5'-diphosphate ribose (cADPR) analogs based on the cyclic inosine 5'-diphosphate ribose (cIDPR) template were synthesized by recently developed stereo- and regioselective N1-ribosylation. Replacing the base N9-ribose with a butyl chain generates inhibitors of cADPR hydrolysis by the human ADP-ribosyl cyclase CD38 catalytic domain (shCD38), illustrating the nonessential nature of the southern ribose for binding. Butyl substitution generally improves potency relative to the parent cIDPRs, and 8-amino-N9-butyl-cIDPR is comparable to the best noncovalent CD38 inhibitors to date (IC50 = 3.3 mu M). Crystallographic analysis of the shCD38:8-amino-N9-butyl-cIDPR complex to a 2.05 angstrom resolution unexpectedly reveals an N1-hydrolyzed ligand in the active site, suggesting that it is the N6-imino form of cADPR that is hydrolyzed by CD38. While HPLC studies confirm ligand cleavage at very high protein concentrations, they indicate that hydrolysis does not occur under physiological concentrations. Taken together, these analogs confirm that the northern ribose is critical for CD38 activity and inhibition, provide new insight into the mechanism of cADPR hydrolysis by CD38, and may aid future inhibitor design.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available